Trial · NCT01435759
Results by group20
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 20
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in Average Systolic Blood Pressure From Augmentation Baseline (Week 8) to Week 16 | Antidepressant + Double-blind Placebo | -0.2 | Standard Deviation 9.55 | mmHg | |
| Change in Average Systolic Blood Pressure From Augmentation Baseline (Week 8) to Week 16 | Antidepressant + Double-blind SPD489 10mg | 0.2 | Standard Deviation 8.58 | mmHg | |
| Change in Average Systolic Blood Pressure From Augmentation Baseline (Week 8) to Week 16 | Antidepressant + Double-blind SPD489 30mg | 0.5 | Standard Deviation 9.17 | mmHg | |
| Change in Average Systolic Blood Pressure From Augmentation Baseline (Week 8) to Week 16 | Antidepressant + Double-blind SPD489 50mg | 3.5 | Standard Deviation 7.82 | mmHg | |
| Change in Average Systolic Blood Pressure From Augmentation Baseline (Week 8) to Week 16 | Antidepressant + Double-blind SPD489 70mg | 2.6 | Standard Deviation 10.55 | mmHg | |
| Change in Average Diastolic Blood Pressure From Augmentation Baseline (Week 8) to Week 16 | Antidepressant + Double-blind Placebo | -0.1 | Standard Deviation 6.69 | mmHg | |
| Change in Average Diastolic Blood Pressure From Augmentation Baseline (Week 8) to Week 16 | Antidepressant + Double-blind SPD489 10mg | -0.9 | Standard Deviation 6.64 | mmHg | |
| Change in Average Diastolic Blood Pressure From Augmentation Baseline (Week 8) to Week 16 | Antidepressant + Double-blind SPD489 30mg | -0.1 | Standard Deviation 7.39 | mmHg | |
| Change in Average Diastolic Blood Pressure From Augmentation Baseline (Week 8) to Week 16 | Antidepressant + Double-blind SPD489 50mg | 2.8 | Standard Deviation 6.58 | mmHg | |
| Change in Average Diastolic Blood Pressure From Augmentation Baseline (Week 8) to Week 16 | Antidepressant + Double-blind SPD489 70mg | 1.9 | Standard Deviation 7.45 | mmHg | |
| Change in Average Pulse Rate From Augmentation Baseline (Week 8) to Week 16 | Antidepressant + Double-blind Placebo | -0.8 | Standard Deviation 9.95 | bpm | |
| Change in Average Pulse Rate From Augmentation Baseline (Week 8) to Week 16 | Antidepressant + Double-blind SPD489 10mg | 0.8 | Standard Deviation 7.32 | bpm | |
| Change in Average Pulse Rate From Augmentation Baseline (Week 8) to Week 16 | Antidepressant + Double-blind SPD489 30mg | 5.3 | Standard Deviation 8.08 | bpm | |
| Change in Average Pulse Rate From Augmentation Baseline (Week 8) to Week 16 | Antidepressant + Double-blind SPD489 50mg | 4.0 | Standard Deviation 9.80 | bpm | |
| Change in Average Pulse Rate From Augmentation Baseline (Week 8) to Week 16 | Antidepressant + Double-blind SPD489 70mg | 6.0 | Standard Deviation 11.25 | bpm | |
| Change in Montgomery-Ǻsberg Depression Rating Scale (MADRS) Total Score From Augmentation Baseline (Week 8) to Week 16 (Double-blind Phase, Dose Response Evaluable Set) | Antidepressant + Double-blind Placebo | -5.4 | 90% Confidence Interval -7.2 to -3.5 | units on a scale | |
| Change in Montgomery-Ǻsberg Depression Rating Scale (MADRS) Total Score From Augmentation Baseline (Week 8) to Week 16 (Double-blind Phase, Dose Response Evaluable Set) | Antidepressant + Double-blind SPD489 10mg | -6.7 | 90% Confidence Interval -8.6 to -4.9 | units on a scale | |
| Change in Montgomery-Ǻsberg Depression Rating Scale (MADRS) Total Score From Augmentation Baseline (Week 8) to Week 16 (Double-blind Phase, Dose Response Evaluable Set) | Antidepressant + Double-blind SPD489 30mg | -5.3 | 90% Confidence Interval -7.1 to -3.4 | units on a scale | |
| Change in Montgomery-Ǻsberg Depression Rating Scale (MADRS) Total Score From Augmentation Baseline (Week 8) to Week 16 (Double-blind Phase, Dose Response Evaluable Set) | Antidepressant + Double-blind SPD489 50mg | -6.1 | 90% Confidence Interval -8.1 to -4.1 | units on a scale | |
| Change in Montgomery-Ǻsberg Depression Rating Scale (MADRS) Total Score From Augmentation Baseline (Week 8) to Week 16 (Double-blind Phase, Dose Response Evaluable Set) | Antidepressant + Double-blind SPD489 70mg | -6.3 | 90% Confidence Interval -8.2 to -4.4 | units on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01435759/results